U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07224269) titled 'Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis' on Oct. 31.
Brief Summary: This will be a single center, open label pilot study to assess the safety and tolerability of terazosin (TZ) at a dose of 5 milligrams (mg) per os (PO) daily for patients with amyotrophic lateral sclerosis (ALS). The primary outcome of this study is to determine whether TZ increases adenosine triphosphate (ATP) levels in ALS. We will measure adverse outcomes, safety, and tolerability of taking TZ. Procedures include blood draws, spirometry, lumbar punctures, fluorodeoxyglucose-positron emission tomography (FDG-PET) scans, questi...